


Global sales pipeline conversion declined by 48% since 2005





1.92%


B2B and B2G Pipeline Conversion as at November 2019

















- 48%

+ 700%









2018 GLOBAL SPEND ON REVENUE IMPROVEMENT

RevenueTEK**

CRM \$1	US48B
---------	-------

MARKETING AUTOMATION \$US6.5B

SALES / MARKETING ANALYTICS \$US17B

SALES TRAINING & COACHING \$US30B

RECRUITMENT \$US3B

EXTERNAL CONSULTING / ADVISORY \$US25B

"BIG DATA" (SALES / MARKETING / CUSTOMER RELATED) \$US80B

\$US209.5B



\$US1.3 TRILLION [\$US1,300,000,000]

ESTIMATED TOTAL AMOUNT SPENT GLOBALLY BETWEEN 2006 – 2019 BY COMPANIES TRYING TO INCREASE REVENUES, WHILE NET PIPELINE CONVERSION FELL BY 48%.

RevenueTEK**

THE SITUATION AS WE ENTER 2020



PIPELINE CONVERSION
CONTINUES TO DECLINE
IN SPITE OF STAGGERING
LEVELS OF INVESTMENT
AND EFFORT TO IMPROVE IT.



MORE REP'S, CHANNELS AND ORGANISATIONS THAN EVER MISS THEIR SALES TARGETS.



SALES CYCLES ARE LONGER, RISKIER AND COSTLIER THAN EVER BEFORE.




TECHNOLOGY IS NOT MAKING ANY APPRECIABLE IMPACT.

"JUST ABOUT EVERY SALES AND MARKETING PERFORMANCE METRIC IS IN DECLINE; OTHER THAN SPENDING ON RECRUITMENT AND TECHNOLOGY AND "BIG-DATA"."



Before COVID, it was largely about growth.





Of finding a way to respond and keep selling through the chaos.

Because if they can't, they'll soon be gone.

Marketing and selling were already insanely complex and challenging tasks. COVID has made them harder, but they were already extraordinarily difficult.






In 2019 alone, they spent \$US220 billion on everything from CRM to training to social media to big data and analytics, all in an attempt to consistently increase their sales output.





In the decade since the GFC, while \$US1.2 trillion was spent trying to improve it, global sales productivity actually declined by 31%.










In 1977 Magnetic Resonance Imaging ("MRI") transformed medical science forever.

Doctors could finally see directly into the enormous complexity of the human body and diagnose exactly what was making patients unwell.





































































Vestpac













Institute of

Australia

Chartered Accountants













exchange







© cerno

tollgrade.



MATHLETICS

















































BROKERCO

420%


BROKERCO

4-20%


BROKERCO

473%
















	START		YEAR 1		YEAR 2
Leads	34.20%	0.0%	34.20%	0.0%	34.2%
Contacts	33.00%	0.0%	33.00%	0.0%	33.0%
Offers	17.00%	0.0%	17.00%	0.0%	17.0%
	1.92%		1.92%		1.9%
Revenue	10.00	0.0%	10.00	0.0%	10.00
COGS	6.00		6.00		6.00
Margin	4.00		4.00		4.00
Overheads	3.00		3.00		3.00
EBIT	1.00		1.00		1.00

	START		YEAR 1		YEAR 2
Leads	34.20%	0.0%	34.20%	0.0%	34.2%
Contacts	33.00%	0.0%	33.00%	0.0%	33.0%
Offers	17.00%	0.0%	17.00%	0.0%	17.0%
	1.92%		1.92%		1.9%
Revenue	10.00	0.0%	10.00	0.0%	10.00
COGS	6.00		6.00		6.00
Margin	4.00		4.00		4.00
Overheads	3.00		3.00		3.00
EBIT	1.00		1.00		1.00


	START		YEAR 1		YEAR 2
Leads	34.20%	0.0%	34.20%	0.0%	34.2%
Contacts	33.00%		33.00%	0.0%	33.0%
Offers	17.00%	J.0%	17.00%	0.0%	17.0%
	1.92%		1.92%		1.9%
Revenue	10.00	0.0%	10.00	0.0%	10.00
COGS	6.00		6.00		6.00
Margin	4.00		4.00		4.00
Overheads	3.00		3.00		3.00
EBIT	1.00		1.00		1.00

	START		YEAR 1	7	YEAR 2
Leads	34.10%	0.0%	34.20%	0.0%	34.2%
Contacts	ف	0.0%	33.00%	0.0%	33.0%
Offers	17.00%	0.0%	1 7.00%	0.0%	17.0%
	1.92%		1.92%		1.9%
Revenue	10.00	0.0%	10.00	0.0%	10.00
COGS	6.00		6.00		6.00
Margin	4.00		4.00		4.00
Overheads	3.00		3.00		3.00
EBIT	1.00		1.00		1.00

	START		YEAR 1		YEAR 2
Leads	34.20%	0.0%	34.20%	0.0%	34.2%
Contacts	33.00%	0.0%	33.00%	0.0%	33.0%
Offers	17.00%	0.0%	17.00%	0.0%	17.0%
	1.92%		1.92%		1.9%
Revenue	10.00	0.0%	10.00	0.0%	10.00
COGS	6.00		6.00		6.00
Margin	4.00		4.00		4.00
Overheads	3.00		3.00		3.00
EBIT	1.00		1.00		1.00

	START		YEAR 1	Ţ	YEAR 2
Leads	34.20%	0.0%	34.20%	0.0%	34.2%
Contacts	33.00%	0.0%	33.00%	0.0%	33.0%
Offers	17.00%	0.0%	17.00%	0.0%	17.0%
	1.92%		1.92%		1.9%
Revenue	10.00	0.0%	10.00	0.0%	10.00
COGS	6.00		6.00		6.00
Margin	4.00		4.00		4.00
Overheads	3.00		3.00		3.00
EBIT	1.00		1.00		1.00







	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	0.0%	33.00%	0.0%	33.0%
Offers	17	0.0%	17.00%	0.0%	17.0%
	1.92%		1.97%		2.0%
Revenue	10.00	2.9%	10.29	0.0%	10.29
COGS	6.00		6.18		6.18
Margin	4.00		4.12		4.12
Overheads	3.00		3.00		3.00
EBIT	1.00		1.12		1.12

	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00	0.0%	33.00%	0.0%	33.0%
Offers	17	0.0%	17.00%	0.0%	17.0%
	1.9∠%		1.97%		2.0%
Revenue	10.00	2.9%	10.29	0.0%	10.29
COGS	6.00		6.18		6.18
Margin	4		4.12		4.12
Overheads	3.00		3.00		3.00
EBIT	1.00		1.12		1.12

	START		YEAR 1	YEAR 2	
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	0.0%	33.00%	0.0%	33.0%
				100000000000000000000000000000000000000	
Offers	17	0.0%	17.00%	0.0%	17.0%
	1.92%		1.97%		2.0%
Revenue	10.00	2.9%	10.29	0.0%	10.29
COGS	6.00		6.18		6.18
Margin	4.		4.12		4.12
Overheads	3.00		3.00		3.00
EBIT	1.00		1.12		1.12



	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	1.0%	34.00%	0.0%	34.0%
Offers	17.00°	0.0%	17.00%	0.0%	17.0%
	1		2.03%		2.0%
Revenue	10.00	6.0%	10.60	0.0%	10.60
COGS	6.00		6.36		6.36
Margin	4.00		4.24		4.24
Overheads	3.00		3.00		3.00
EBIT	1.00		1.24		1.24

	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	1.0%	34.00%	0.0%	34.0%
Offers	17.00°	0.0%	17.00%	0.0%	17.0%
	1		2.03%		2.0%
Revenue	10.00	6.0%	10.60	0.0%	10.60
COGS	6.00		6.36		6.36
Margin			4.24		4.24
Overheads	3.00		3.00		3.00
EBIT	1.00		1.24		1.24

	START	START YEAR			YEAR 2
	JIAN		I LAN ±		I LAN Z
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	1.0%	34.00%	0.0%	34.0%
Offers	17.00°	0.0%	17.00%	0.0%	17.0%
	1		2.03%		2.0%
Revenue	10.00	6.0%	10.60	0.0%	10.60
COGS	6.00		6.36		6.36
Margin	4,		4.24		4.24
Overheads	3.00		3.00		3.00
EBIT	1.00		1.24		1.24



	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	1.0%	34.00%	0.0%	34.0%
Offers	17.00%	1.0%	18.00%	0.0%	18.0%
	1.929		2.15%		2.2%
Revenue	10.50	12.3%	11.23	0.0%	11.23
COGS	6.00		6.74		6.74
Margin	4.00		4.49		4.49
Overheads	3.00		3.00		3.00
EBIT	1.00		1.49		1.49

	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	1.0%	34.00%	0.0%	34.0%
Offers	17.00%	1.0%	18.00%	0.0%	18.0%
	1.92°		2.15%		2.2%
Revenue	10. 40	12.3%	11.23	0.0%	11.23
COGS	F		6.74		6.74
Margin	ال		4.49		4.49
Overheads	3.00		3.00		3.00
EBIT	1.00		1.49		1.49

	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	0.0%	35.2%
Contacts	33.00%	1.0%	34.00%	0.0%	34.0%
Offers	17.00%	1.0%	18.00%	0.0%	18.0%
	1.92°		2.15%		2.2%
Revenue	10. 41	12.3%	11.23	0.0%	11.23
COGS	F		6.74		6.74
Margin	٥١		4.49		4.49
Overheads	3.00		3.00		3.00
EBIT	1.00		1.49		1.49



	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	1.0%	36.2%
Contacts	33.00%	1.0%	34.00%	1.0%	35.0%
Offers	17.00%	1.0%	18.00	1.0%	19.0%
	1.92%				2.4%
		i i			
Revenue	10.00	12.3%	11.23	11.7%	12.55
COGS	6.00		6.74		7.53
Margin	4.00		4.49		5.02
Overheads	3.00		3.00		3.00
EBIT	1.00		1.49		2.02

	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	1.0%	36.2%
Contacts	33.00%	1.0%	34.00%	1.0%	35.0%
Offers	17.00%	1.0%	18.6	1.0%	19.0%
	1.92%		1%		2.4%
Revenue	10.00	12.3%	11.23	11.7%	12.55
COGS	6.00		6 -		7.53
Margin	4.00				5.02
Overheads	3.00		3.00		3.00
EBIT	1.00		1.49		2.02

	START		YEAR 1		YEAR 2
Leads	34.20%	1.0%	35.20%	1.0%	36.2%
Contacts	33.00%	1.0%	34.00%	1.0%	35.0%
Offers	17.00%	1.0%	18.0	1.0%	19.0%
	1.92%		1/0		2.4%
Revenue	10.00	12.3%	11.23	11.7%	12.55
COGS	6.00		6 -		7.53
Margin	4.00				5.02
Overheads	3.00		3.00		3.00
EBIT	1.00		1.49		2.02

+ 102%



RevenueTEK**

MARGINAL GAIN EQUATION

1%

If you already think you're as good as you can be, you will defend the status quo and become defensive when people point out your weaknesses.

If you think you can improve, you will be oriented towards a search for marginal gains, and you will be thrilled when people point out your weaknesses, because it gives you a chance to fix them and become even better.

It is a completely different way of seeing the world.

NOT EVERYTHING THAT COUNTS, GETS COUNTED.

NOT EVERYTHING THAT GETS COUNTED, COUNTS.

START THINKING ABOUT – AND MEASURING, PROGRESSION, VELOCITY AND LEAKAGE.












- Untroubled & Unaware
- Feel & Acknowledge Pain
- Initial Research
- Identify & Clarify Needs
- Identify Solution Options
- Solicit Offers
- Receive & Review Proposals
- Select Preferred Supplier
- Engage



	100	Untroubled & Unaware
65%	65	Feel & Acknowledge Pain
50%	32	Initial Research
75%	24	Identify & Clarify Needs
75%	18	Identify Solution Options
50%	9	Solicit Offers
65%	5	Receive & Review Proposals
30%	2	Select Preferred Supplier
90%	1	Engage

The Logic of Marginal Gain Theory

- Buyer's journey
- Number of progressions
- Tactics to *progress* and *accelerate*
- Drive progression and velocity
- Measure *progression* and *velocity*
- Improve progression *incrementally*

Conservative Buyers

- More comfortable with people than technology
- Risk averse
- Price sensitive
- Highly reliant on trusted advisors and referrers
- Like complete, proven solutions
- Can see benefit in value-added services, but resist paying for them



Oh, interesting. Let me just write that on my list of things I don't give


a shit about.



1. Uniqueness



Challenger Selling





3. Trust



4. Proximity



5. "KVP"



....Killer Value Proposition!





Discovered our "Problem statement"

RUST

Prospects who have this PROBLEM with their current provider




Created Content that spoke to our prospects about this problem






Not just Insurance - Different conversations on TRUST

When the prospect realised they have a TRUST problem...



BroCo are there to help solve their problem



MARKETING **SALES Generating Leads Converting Leads**

Developed conversation & email scripts



Matured our sales process to speak to prospects at the right time


So we don't get ignored!



"Speak now, you may."

Reviewed current pipeline against our IDEAL CLIENT and PROBLEM

Anyone that is not our IDEAL CLIENT or doesn't have TRUST PROBLEM we stopped 'wasting' time on



Introduced STRATEGIC ACCOUNT PLANNING (SAP) for specific prospects



A clinical review process that stops us wasting time on non-productive effort whilst focusing key resources where best value, and revenue, can be achieved



OUTCOMES?

Sales improved by 20% per year

Profit improved by 100% per year

